Member Posts > Cardiol Therapeutics' CRD-38: A Novel Therapy for Addressing Heart Failure at Its Core
Millions of people worldwide suffer from HFpEF, a condition with few effective treatments. Cardiol Therapeutics is pioneering a new path with CRD-38, an investigational subcutaneous therapy that has demonstrated compelling pre-clinical results.
A recent study published in The Journal of the American College of Cardiology: Basic to Translational Science highlights CRD-38's ability to improve heart function, suppress inflammation, and prevent cardiac deterioration.
Study Findings
• Improved Ejection Fraction: CRD-38 enhances cardiac output, ensuring more efficient blood circulation.
• Structural Maintenance: The drug prevents hypertrophy and fibrosis, two major causes of HFpEF progression.
• Inflammation Control: CRD-38 lowers inflammatory cytokines, reducing the risk of cardiac damage.
• Energy Preservation: It maintains mitochondrial function, preventing cardiac stress.
The Future of CRD-38
CRD-38 is set to enter clinical trials, where it will be further evaluated for safety and efficacy in human patients.

#CardiolTherapeutics #BiotechInvesting #ClinicalTrials #PharmaStocks #CBDTherapeutics #HeartHealth #StockMarket #InvestingInBiotech #HealthcareInnovation #OrphanDrug #Myocarditis #Pericarditis #FDAApproval #GrowthStocks #MedicalBreakthroughs